Categories: Health

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

 | Source: Milestone Scientific, Inc.

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company’s financial results for the second quarter ended June 30, 2025, as well as the company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster4.com/Webcast/Page/2306/52876.

An audio replay of the call will be available through Friday, August 29th, 2025, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 52876.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS), a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

GlobeNews Wire

Recent Posts

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids…

1 hour ago

Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over…

1 hour ago

GigaDevice Launches GD25NX Series xSPI NOR Flash with Dual-Voltage Design

BEIJING--(BUSINESS WIRE)--#Automotive--GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and…

1 hour ago

Friendly Fraud Expected to Increase by 25% Between Thanksgiving and Cyber Monday, Warns ACI Worldwide

ACI’s Payments Intelligence approach offers merchants complete journey protection—stopping friendly fraud and chargeback abuse in…

1 hour ago

OSF Digital Expands Its Global Presence with a New Office in Hyderabad, India

Strengthening delivery excellence and regional support for clients worldwideHYDERABAD, India, Nov. 25, 2025 /PRNewswire/ --…

5 hours ago

UNIDO Announces Winners of Inaugural One World Sustainability Awards in Riyadh

RIYADH, Saudi Arabia, Nov. 24, 2025 /PRNewswire/ -- UNIDO has announced the winners of the…

5 hours ago